- NCIt
- C227225
Loading cancer entity…
Loading cancer entity…
Clinical trials
12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY |
| 1 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05239546 | Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers(NAIO) | recruiting | Phase 2 | 25 | University of IowaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07409844 | Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer(RESET C2) | not yet recruiting | Phase 2 | 152 | Ismail GögenurOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06414304 | Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy(BLOOMSI) | completed | — | 30 | OncoAtlas LLCINDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06613165 | Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer | recruiting | — | 100 | Xijing HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials